# DETERRED (NCT02525757)

> MPDL3280A With Chemoradiation for Lung Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus carboplatin plus paclitaxel
- Indication: unresectable non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02525757
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Lung Cancer; Non-Small Cell Lung Cancer
- Interventions: MPDL3280A; Carboplatin; Paclitaxel; Radiation Therapy
- Enrollment: 52
- Primary outcome: Time to Toxicity

## Indexed commentary on DETERRED so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 15 posts on X
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=deterred-nct02525757

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02525757", "email": "<work email>"}; the inbox owner confirms by the emailed link.